4-((1,2-dihydro-2-oxo-6-quinolinyl)oxy)-N-ethyl-N-phenyl-butanamide | 69592-38-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-((1,2-dihydro-2-oxo-6-quinolinyl)oxy)-N-ethyl-N-phenyl-butanamide
• 英文别名: 6-[3-(N-Ethylanilinocarbonyl)propoxy]carbostyril；N-ethyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]-N-phenylbutanamide
• CAS: 69592-38-7
• 化学式: C₂₁H₂₂N₂O₃
• 分子量: 350.417
• InChiKey: XPRXUARMKOMPCN-UHFFFAOYSA-N

物化性质

• 沸点：
  589.6±50.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use
  申请人：——

  公开号：US20040087591A1

  公开（公告）日：2004-05-06

  The invention describes novel compositions containing at least one phosphodiesterase inhibitor, and at least one compound that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).

  该发明描述了一种新型组合物，其中包含至少一种磷酸二酯酶抑制剂，以及至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的化合物。该发明还提供了治疗或预防男性和女性性功能障碍、增强男性和女性性反应以及治疗或预防由环磷鸟苷3′，5′-单磷酸（cGMP）代谢增加引起的疾病的方法，如高血压、肺动脉高压、充血性心力衰竭、肾功能衰竭、心肌梗塞、稳定、不稳定和变异性（普林兹梅塔尔）心绞痛、动脉粥样硬化、心脏水肿、肾功能不全、肾病性水肿、肝性水肿、中风、哮喘、支气管炎、慢性阻塞性肺疾病（COPD）、囊性纤维化、痴呆、免疫缺陷、早产、痛经、良性前列腺增生（BPH）、膀胱出口梗阻、失禁、血管通畅度降低的疾病，例如经皮冠状动脉成形术后（post-PTCA）、外周血管疾病、变应性鼻炎、青光眼以及肠道运动障碍等疾病的特征性障碍。
• US4298739A
  申请人：——

  公开号：US4298739A

  公开（公告）日：1981-11-03
• US6221881B1
  申请人：——

  公开号：US6221881B1

  公开（公告）日：2001-04-24
• US6331543B1
  申请人：——

  公开号：US6331543B1

  公开（公告）日：2001-12-18
• US6462044B2
  申请人：——

  公开号：US6462044B2

  公开（公告）日：2002-10-08